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Abstract
Background: Infection by the pandemic influenza A (H1N1/09) virus resulted in significant pathology among specific ethnic
groups worldwide. Natural Killer (NK) cells are important in early innate immune responses to viral infections. Activation of
NK cells, in part, depend on killer-cell immunoglobulin-like receptors (KIR) and HLA class I ligand interactions. To study
factors involved in NK cell dysfunction in overactive immune responses to H1N1 infection, KIR3DL1/S1 and KIR2DL2/L3
allotypes and cognate HLA ligands of H1N1/09 intensive-care unit (ICU) patients were determined.
Methodology and Findings: KIR3DL1/S1, KIR2DL2/L3, and HLA -B and -C of 51 H1N1/09 ICU patients and 105 H1N1-
negative subjects (St. Theresa Point, Manitoba) were characterized. We detected an increase of 3DL1 ligand-negative pairs
(3DL1/S1
+ Bw6
+ Bw4
2), and a lack of 2DL1 HLA-C2 ligands, among ICU patients. They were also significantly enriched for
2DL2/L3 ligand-positive pairs (P,0.001, Pc,0.001; Odds Ratio:6.3158, CI95%:2.481–16.078). Relative to St. Theresa
aboriginals (STh) and Venezuelan Amerindians (VA), allotypes enriched among aboriginal ICU patients (Ab) were: 2DL3
(Ab.VA, P=0.024, Pc=0.047; Odds Ratio:2.563, CI95%:1.109–5.923), 3DL1*00101 (Ab.VA, P,0.001, Pc,0.001),
3DL1*01502 (Ab.STh, P=0.034, Pc=0.268), and 3DL1*029 (Ab.STh, P =0.039, Pc=0.301). Aboriginal patients ligand-
positive for 3DL1/S1 and 2DL1 had the lowest probabilities of death (Rd)( R d=28%), compared to patients that were 3DL1/
S1 ligand-negative (Rd=52%) or carried 3DL1*029 (Rd=52%). Relative to Caucasoids (CA), two allotypes were enriched
among non-aboriginal ICU patients (NAb): 3DL1*00401 (NAb.CA, P,0.001, Pc,0.001) and 3DL1*01502 (CA,NAb,
P=0.012, Pc=0.156). Non-aboriginal patients with ligands for all three KIRs (3DL1/S1, 2DL2/L3, and 2DL1) had the lowest
probabilities of death (Rd=36%), compared to subjects with 3DL1*01502 (Rd=48%) and/or 3DL1*00401 (Rd=58%).
Conclusions: Specific KIR3DL1/S1 allotypes, 3DL1/S1 and 2DL1 ligand-negative pairs, and 2DL2/L3 ligand-positive pairs
were enriched among ICU patients. This suggests a possible association with NK cell dysfunction in patients with overactive
immune responses to H1N1/09, leading to severe disease.
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Introduction
The recent pandemic influenza A (H1N1/09) virus, relative to
seasonal influenza, was observed to have higher transmissibility,
albeit with lower mortality rates [1,2]. Although there were more
than 622,482 reported cases worldwide as of November 2009
[3,4], overactive immune responses to H1N1/09 infections leading
to significant pathology were reported to be highly prevalent
among youths and young adults. Recently, the basis for this
observation was suggested to be a lack of antigenic site recognition
for the hemagglutinin structure among those age groups [5,6].
Nonetheless, those of specific ethnic backgrounds were also ob-
served to be disproportionately affected, namely aboriginal and
minority groups [7–11]. Although the factors behind the dis-
proportionate impact of H1N1/09 remain to be fully elucidated,
there is some evidence to suggest a role for natural killer (NK) cells
in the control of influenza viral loads.
The importance of NK cells was suggested in a recent study,
where NK cell frequencies were found to be significantly reduced
in patients with severe responses to H1N1/09 infections, relative
to mild cases and healthy controls [12]. On the other hand, CD8
+
effector T cells, regardless of patient disease status, were detected
at normal levels. A study of NK cells in infected mice also showed
that reduced NK cell activity in the earlier stages led to
significantly increased viral growth [13].
NK cells function as the primary innate immune response against
viruses and tumours and are capable of inducing stimulatory and
regulatory effects on the adaptive immune response [14–16]. Their
functions are determined by a broad array of activating and
inhibitory receptors [17]. Killer-cell immunoglobulin-like receptors
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inhibitory capacities that recognize HLA Class I ligands [18,19],
along with a few variants that possess activating functions. In the
context of all known KIR variants in humans, the KIR3DL1/S1
subset is widespread and encode for both an inhibitory (3DL1) and
activating(3DS1)receptor[19].KIR3DL1receptorsrecognize class
I HLA-B proteins that carry a Bw4 motif [20], while HLA-B Bw4-
80I proteins are the putative ligands of KIR3DS1 [21]. Analogous
inhibitory KIR subsets, such as KIR2DL1 and KIR2DL2/L3,
recognize HLA-C2 and HLA-C1 ligands, respectively [22,23].
Given the independent diversities of KIR and HLA, there likely
exist combinations which can variably influence the efficacy of NK
cell responses in the control of viral infections due to the presence of
certain NK cell receptor/ligand pairs [24–26].
To date, there have been no published reports pertaining to
KIR receptors and their ligands, in relation to NK cell
dysfunction, in severe cases of H1N1/09 infections. Identification
of potential associations of specific KIR allotypes and their ligands
with severe responses to H1N1/09 infections may assist in the
predetermination of populations most at risk via information on
frequencies of molecular immune response allotypes. In this study,
we compared H1N1/09 ICU patients with H1N1-negative
subjects from St. Theresa Point and similar world populations.
We investigated KIR3DL1/KIR3DS1 and KIR2DL2/KIR2DL3
in this study, as each pair share the same locus, encode for both
inhibitory and/or activating receptors, and their HLA ligands are
highly polymorphic [27].
Results
KIR3DL1/S1 allotype and KIR2DL2/L3 frequencies of
H1N1/09 ICU patients
The KIR3DL1/S1 and KIR2DL2/L3 frequencies of ICU patients
are summarized in Table 1. In total, fourteen 3DL1 and two 3DS1
allotypes were detected. 3DS1*01301 was the most prevalent (26.5%),
followed by 3DL1*00101(15.7%), 3DL1*01502(15.7%), 3DL1*00401
(9.8%), and 3DL1*00501(8.8%). Three allotypes, 3DS1*01301, 3DL1
*00101, and *01502, were found to account for 70% of allotypes
among ICU patients of aboriginal descent (Ab). Greater diversity was
found among patients of non-aboriginal descent (NAb), as five allotypes
accounted for a combined frequency of 77%: 3DS1*01301, 3DL1
*00401, *00101, *01502, *002.
KIR2DL2/L3 were detected in all patients, with a high number
of patients carrying only 2DL3 allotypes (Ab, 70%; NAb, 54.8%).
Patients with only 2DL2 were rare among both ICU subgroups
(Ab, 5%; NAb, 3.2%). These results were consistent with another
study on First Nations KIR gene profiles [28]. Differences in
2DL2/L3 distributions between Ab and St. Theresa Point (STh)
subjects were not statistically significant.
Enrichment of KIR3DL1/S1 allotypes in H1N1/09 ICU
patients of aboriginal descent
In order to further characterize the diversity and distribution of
allotypes among Ab patients, we compared those with high
frequencies to St. Theresa Point subjects. This was a viable group
Table 1. KIR3DL1/S1 allele frequencies of ICU patients and St. Theresa aboriginals.
ICU Patients, C
All (2n = 102) Ab (2n=40) NAb (2n=62) STh (2n=210) P (Pc)
KIR Allele 2n AF 2n AF 2n AF 2n AF Ab vs STh
3DL1*00101 16 15.7% 8 20.0% 8 12.9% 46 21.9% 0.486
3DL1*002 7 6.9% 0 0.0% 7 11.3% 1 0.5% 1.000
3DL1*00401 10 9.8% 0 0.0% 10 16.1% 0 0.0% -
3DL1*00402 2 2.0% 0 0.0% 2 3.3% 0 0.0% -
3DL1*00501 9 8.8% 3 7.5% 6 9.7% 38 18.1% 0.108
3DL1*007 4 3.9% 1 2.5% 3 4.8% 0 0.0% 0.163
3DL1*008 1 1.0% 0 0.0% 1 1.6% 0 0.0% -
3DL1*009 1 1.0% 0 0.0% 1 1.6% 0 0.0% -
3DL1*01501 0 0.0% 0 0.0% 0 0.0% 0 0.0% -
3DL1*01502 16 15.7% 8 20.0% 8 12.9% 16 7.6% 0.034 (0.268)
1
3DL1*019 0 0.0% 0 0.0% 0 0.0% 0 0.0% -
3DL1*020 1 1.0% 0 0.0% 1 1.6% 0 0.0% -
3DL1*029 4 3.9% 4 10.0% 0 0.0% 5 2.4% 0.039 (0.301)
2
3DL1*051 1 1.0% 1 2.5% 0 0.0% 1 0.5% 0.300
3DS1*010 3 2.9% 3 7.5% 0 0.0% 5 2.4% 0.119
3DS1*01301 27 26.5% 12 30.0% 15 24.2% 98 46.7% 0.055
3DL1 72 70.6% 25 62.5% 47 75.8% 107 51.0% 0.227
3DS1 30 29.4% 15 37.5% 15 24.2% 103 49.0%
2DL2 22 21.6% 7 17.5% 15 24.2% 31 14.8% 0.635
2DL3 80 78.4% 33 82.5% 47 75.8% 179 85.2%
AF, allele frequency; Ab, Aboriginal; NAb, Non-aboriginal.
STh, St. Theresa aboriginals; C, H1N1 confirmed cases.
1Odds Ratio:3.031(CI95%:1.199–7.663);
2Odds Ratio:4.556(CI95%:1.167–17.779).
doi:10.1371/journal.pone.0029200.t001
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responses during the first wave of the pandemic [29,30]. Because
aboriginal ICU patient samples were derived from hospitals across
the country, they were assumed to be more ethnically diverse than
St. Theresa aboriginals. This was confirmed when their distribu-
tions of HLA-B and C were compared.
Nine different allotypes were detected between Ab and STh
(Table 1). 3DS1*01301 and 3DL1*00101 were especially
widespread among both groups. Similar to Ab patients, a lack of
diversity was detected among the STh subjects, as three allotypes
(3DS1*01301, 3DL1*00101, and *00501) accounted for a
combined frequency of 86.7%.
Prior to correction for multiple comparisons, two allotypes were
found to be significantly enriched among Ab patients:
3DL1*01502 (Ab.STh, P=0.034, Pc=0.268; Odds Ratio:3.031,
CI95%:1.199–7.663) and 3DL1*029 (Ab.STh, P=0.039,
Pc=0.301; Odds Ratio:4.556, CI95%:1.167–17.779). 3DS1*010
was detected at a higher frequency in Ab patients, but the
difference was not statistically significant (Ab.STh, P=0.119).
Lack of KIR3DL1/S1 and HLA-B Bw4 ligand pairs in H1N1/
09 ICU patients
In the absence of cognate ligands, the presence and function of
KIR3DL1/S1 receptors are deemed negligible, due to their
inability to elicit a relevant response within NK cells [18,20,21].
Subjects detected as KIR3DL1/S1
+ HLA-B Bw6
+ Bw4
2 were
considered to be ligand-negative. To determine the relative degree
of ligand-negative pairs present among ICU patients, we
determined the prevalence of 3DL1/S1 and their cognate ligands
(Bw4
+), among the ICU patients and St. Theresa subjects. Overall,
compared to STh subjects, 3DL1 ligand-negative pairs were found
to be proportionally higher in H1N1/09 ICU patients
(ICU.STh, P=0.093) (Table 2), albeit not statistically different
due to the small sample size. In contrast, 3DL1/S1-Bw4
+ pairs
were common among the healthy STh subjects (81%). Of the
highly prevalent 3DL1/S1 allotypes that were common among
both groups, the frequencies of several ligand-negative pairs
(3DL1*00101, 3DL1*01502, 3DS1*010, and 3DS1*01301) were
much higher among the H1N1/09 patient groups.
Enrichment of KIR2DL2/L3 and HLA-C C1 ligand pairs
among H1N1/09 ICU patients
In order to further determine the frequency of other functional
KIR allotype-ligand relationships, the distribution of KIR2DL2/
L3 and HLA-C1/C2 were determined. Subjects with 2DL2/L3
+
C1
+ C2
+/2 were considered to be ligand-positive (Table 2). All
NAb patients were ligand-positive. Compared to STh subjects,
ligand-positive pairs were significantly higher in H1N1/09 ICU
patients overall (P,0.001, Pc,0.001; Odds Ratio:6.3158,
CI95%:2.481–16.078). Conversely, there was a significant lack
of C2 allotypes (KIR2DL1 ligands) among NAb patients, as
compared to both Ab and STh subjects (NAb (12.9%),Ab
(50.0%),STh (68.1%), PNAbvsAb,0.001, Pc,0.001; PNAbvsSTh,
0.001, Pc,0.001).
Comparison of KIR3DL1/S1 and KIR2DL2/L3 frequencies
between H1N1/09 ICU subgroups and world populations
During the initial waves of the H1N1/09 pandemic, several
populations were disproportionately affected by overactive im-
mune responses to infections. We compared the frequencies of
KIR3DL1/S1 allotypes enriched among the ICU subgroups (Ab
and NAb) to that of analogous populations in the world; the
Venezuelan Amerindians (VA) and Caucasoids (CA) of various
countries [31]. The VA group consisted of three Amerindian
tribes: the Yucpa, Bari, and Warao [32]. The CA group consisted
mainly of six different populations: England, Georgia, Spain,
Turkey, USA California, and USA European [33,34].
The Amerindian tribes were similarly found to lack diversity in
3DL1/S1 and their most prevalent allotypes were 3DS1*01301,
3DL1*005, and *01502 (Table 1, 3). 3DL1*00101, common to
both Ab and STh subjects, was absent in VA subjects (VA,Ab,
Table 2. Comparison of KIR3DL1/S1 allotypes in the presence
or absence of their ligands within H1N1- confirmed ICU
patients and St. Theresa aboriginals.
ICU patients, Confirmed
KIR Allele Ab Nab STh
3DL1*00101
Bw4
+ 5 (71.4%) 5 (62.5%) 37 (86.0%)
Bw6
+,B w 4
2 2 (28.6%) 3 (37.5%) 6 (14.0%)
3DL1*002
Bw4
+ 0 (0%) 4 (66.7%) 1 (100%)
Bw6
+,B w 4
2 0 (0%) 2 (33.3%) 0 (0%)
3DL1*00501
Bw4
+ 2 (66.7%) 4 (66.7%) 25 (69.4%)
Bw6
+,B w 4
2 1 (33.3%) 2 (33.3%) 11 (30.6%)
3DL1*01502
Bw4
+ 4 (57.1%) 5 (71.4%) 15 (93.7%)
Bw6
+,B w 4
2 3 (42.9%) 2 (28.6%) 1 (6.3%)
3DS1*10
Bw4
+ 1 (33.3%) 0 (0%) 5 (100%)
Bw6
+,B w 4
2 2 (66.7%) 0 (0%) 0 (0%)
3DS1*01301
Bw4
+ 9 (90.0%) 9 (75.0%) 56 (77.8%)
Bw6
+,B w 4
2 1 (10.0%) 3 (25.0%) 16 (22.2%)
3DL1
Bw4
+ 13 (72.2%) 18 (64.3%) 63 (79.8%)
Bw6
+,B w 4
2 5 (27.8%) 10 (35.7%) 16 (20.3%)
3DS1
Bw4
+ 10 (76.9%) 9 (75.0%) 61 (79.2%)
Bw6
+,B w 4
2 3 (23.1%) 3 (25.0%) 16 (20.8%)
3DL1
*
Bw4
+ 31 (67.4%) 85 (81.0%)
Bw6
+,B w 4
2 15 (32.6%) 20 (19.0%)
2DL2
C1
+ 4 (66.7%) 14 (100%) 14 (45.2%)
C1
2,C 2
+ 2 (33.3%) 0 (0%) 17 (54.8%)
2DL3
C1
+ 13 (68.4%) 30(100%) 57 (54.3%)
C1
2,C 2
+ 6 (31.6%) 0 (0%) 48 (45.7%)
2DL2/L3
**
C1
+ 45 (88.2%) 57 (54.3%)
C1
2,C 2
+ 6 (11.8%) 48 (45.7%)
Ab, Aboriginal; NAb, Non-aboriginal; STh, St. Theresa aboriginals.
**P,0.001, Pc,0.001.
*P,0.10.
doi:10.1371/journal.pone.0029200.t002
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KIR2DL2 and KIR2DL3 allotypes were found to be significantly
reduced and enriched, respectively, in comparison to VA subjects
(Ab.VA, P=0.024, Pc=0.047; Odds Ratio:2.563, CI95%:1.109–
5.923).
World Caucasoids were highly diversified for 3DL1/S1
(Table 3). Eighty-seven percent of NAb ICU patients were
Caucasoids and when compared to the CA group, 3DL1*00401
was significantly found to be enriched (CA,NAb, P,0.001,
Pc,0.001; Odds Ratio:5.460, CI95%:2.717–10.970). Prior to
correction for multiple comparisons, 3DL1*01502 was also
markedly enriched in NAb (CA,NAb, P=0.012, Pc=0.156;
Odds Ratio:2.163, CI95%:1.019–4.593). Differences in 2DL2/L3
between NAb patients and the CA group were not statistically
significant.
APACHE II score comparison between H1N1/09 ICU
subgroups and allotype/ligand pairs
APACHE II is a severity of disease classification system,
commonly used for ICU patients, which calculates risk of hospital
death on the basis of twelve routine physiologic measurements and
their degree of divergence from typical thresholds [35]. Total
APACHE II scores were calculated for all H1N1/09 ICU patients
and probabilities of death (Rd) were determined (Table 4). Because
KIR3DS1 has only been shown to bind to Bw4-80I ligands [26],
3DS1
+/3DL1
2 Bw4-80T
+ 80I
2 pairs were considered to be
ligand-negative, when correlating allotype-ligand pairs with
APACHE II scores.
Among Ab patients, the mean probability of death was 38%
(Range: 8%–75%). Low death rates were consistently observed in
subjects that were 3DL1/S1 Bw4
+ ligand-positive and in
combination with HLA-C2 (Rd=28%). No notable differences
were found based solely on the presence of 2DL2/L3 C1
+/2 pairs.
Of the 3DL1 allotypes enriched in aboriginal patients, only
3DL1*029, which was rare in most ethnic groups with exception
to the Yucpa Amerindians from Venezuela [31], was associated to
a higher probability of death (Rd=52%). Because of the variations
in binding affinity of 2DL2 and 2DL3 to HLA-C1 [36], the disease
severities between patients with these allotypes were compared.
Differences in death rates were found between 2DL2
+ (Rd=21%)
and 2DL3
+ 2DL2
2 patients (Rd=46%).
Non-aboriginal ICU patients had slightly higher probabilities of
death with a mean of 40% (Range: 8%–80%). All NAb patients were
2DL2/L3 C1
+ ligand-positive. Contrary to Ab patients, low
probabilities of death (Rd=39%) were found in 3DL1/S1 Bw6
+
ligand-negative pairs. However, a comparable death rate (Rd=36%)
was also observed in 3DL1/S1 Bw4
+ HLA-C2
+ subjects, which may
indicate either a lack of effect by 3DL1/S1 on disease severity in non-
aboriginals, or confounding due to an absence of 2DL2/L3 C1
+
ligand-negative patients. Patients with ligands for all three KIRs
Table 3. Comparison of KIR3DL1/S1 allele frequencies between ICU patients and analogous world populations.
ICU Patients, C Ethnic Groups P (Pc)
KIR Allele Ab NAb Va
a,b Ca
a,c Ab vs VA NAb vs CA
3DL1*001 0.200 0.129 0.000
6 0.162
6 ,0.001 (,0.001)
1 0.603
3DL1*002 0.000 0.113 0.000 0.120 - 1.000
3DL1*00401 0.000 0.161 0.002 0.034 1.000 ,0.001 (,0.001)
2
3DL1*00402 0.000 0.033 0.000 0.119 - 0.029
3DL1*005 0.075 0.097 0.128
6 0.145
6 0.455 0.841
3DL1*007 0.025 0.048 0.002 0.033 0.154 0.167
3DL1*008 0.000 0.016 0.005 0.051 0.222 1.000
3DL1*009 0.000 0.016 0.000 0.020 - 0.562
3DL1*01501 0.000 0.000 0.000 0.004 - 1.000
3DL1*01502 0.200 0.129 0.373 0.064 0.038 0.012 (0.156)
3
3DL1*019 0.000 0.000 0.000 0.001 - 1.000
3DL1*020 0.000 0.016 0.000 0.008 - 0.386
3DL1*029 0.100 0.000 0.065 0.001 0.336 1.000
3DS1*01301 0.300 0.242 0.407 0.233 0.239 0.878
3DL1 0.625 0.758 0.578 0.802
d 0.619 0.424
3DS1 0.375 0.242 0.422 0.198
d
2DL2 0.175 0.242 0.352 0.320
d 0.024 (0.047)
4 0.220
2DL3 0.825 0.758 0.648 0.680
d
Ab, Aboriginal; NAb, Non-aboriginal; VA, Venezuelan Amerindian; CA, Caucasoid.
3DL1*051, 3DS1*010 comparisons not available.
aAllele frequencies derived from Allele frequency net (28).
b2n=460;
c2n=4056;
d2n=17,680.
6Frequencies derived from low-resolution data.
1Odds Ratio:infinite;
2Odds Ratio:5.460(CI95%:2.717–10.970);
3Odds Ratio:2.163(CI95%:1.019–4.593);
4For 2DL2, Odds Ratio:0.390(CI95%:0.169–0.902); For 2DL3, Odds Ratio:2.563(CI95%:1.109–5.923).
doi:10.1371/journal.pone.0029200.t003
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(Rd=36%). 3DL1*01502 and 3DL1*00401, allotypes enriched in
non-aboriginal patients, were correlated with high disease severity
(Rd=48%; and R d=58%, respectively). There were no significant
differences in disease severity between 2DL2
+(Rd=38%)and2DL3
+
2DL2
2 (Rd=42%)patients.
Discussion
The objective of this study was to identify KIR3DL1/S1 and
KIR2DL2/L3 allotypes, and corresponding ligands, enriched in
aboriginal and non-aboriginal H1N1/09 ICU patients from the initial
2009 H1N1 pandemic waves. The premise was that specific allotypes
and/or ligand combinations could predispose patients towards severe
responses to H1N1/09 infections. In a general population, only a
small proportion of individuals will develop such overactive immune
responses [37–39]. The enrichment of specific KIR allotypes was
evident when viewed in comparison to an H1N1-negative control
population, St. Theresa Point; a First Nations community that was
severely impacted during the firs ta n ds e c o n dw a v eo ft h ep a n d e m i c
[29,30]. Specific KIR allotype enrichment was also present, relative to
Amerindians and world Caucasoids. Despite the small sample size of
the ICU patients, several significant differences between groups were
o b s e r v e d .A st h i si sa ne x p l o r a t o r ystudy, further confirmation of the
findings in future studies will be necessary.
In general, patients and populations of aboriginal descent were
all found to lack 3DL1/S1 diversity, relative to world Caucasoids
and ICU non-aboriginal patients. Although nine allotypes were
detected, four allotypes accounted for the majority among all
aboriginal subjects. This relatively low degree of diversity may
nonetheless confer a greater susceptibility to infectious diseases, in
general [11]. Additionally, 2DL3 allotypes were prevalent among
ICU and St. Theresa subjects, in addition to a lack of 2DL2/2DL2
(homozygous) allotype carriers, especially among St. Theresa
subjects. Enrichment of 2DL3 was also detected in aboriginal
patients, in comparison to Venezuelan Amerindians. However, the
2DL2/L3 distributions between all other groups were similar and
were consistent with the report from a study on KIR profiles in
First Nations and Caucasoids of European Descent [28].
Highly expressed allotypes of KIR3DL1 (3DL1*001, *002,
01502), defined by their expression levels and/or inhibitory
capacities [40–42], were common to both healthy St. Theresa
and H1N1/09 ICU subjects. Yet among the ICU patients, these
allotypes were frequently found ligand-negative. Overall, there was
a larger proportion of 3DL1 ligand-negative ICU patients, relative
to St. Theresa subjects. Although presumptive, it is highly possible
then that, in conjunction with their cognate ligands, KIR3DL1
may play a partial role in preventing infection or inhibiting the
development of severe responses.
Conversely, the significant enrichment of 2DL2/L3 ligand-
positive pairs in ICU patients, in comparison to St. Theresa
subjects, may imply that 2DL2/L3-ligand interactions contribute
to greater disease severity. APACHE II scores (probability of
hospital death) and available KIR/ligand data further suggested
this possibility. Interestingly, correlations between disease severity
and absence of 3DL1/S1 ligands and 2DL2 allotypes, were
evident in aboriginal ICU patients only. The lack of clarity among
non-aboriginal patients may be due to a lack of C2 ligands that
was specifically observed in non-aboriginal ICU patients, and the
expected high prevalence of their corresponding 2DL1 allotypes in
both First Nations and Caucasoids of European descent [28,31].
Nonetheless, the small proportion of non-aboriginal patients with
ligands for all three KIR subtypes had the least severe responses.
Taken together, severe responses to H1N1/09, among other
factors, may be dependent on 3DL1/S1, 2DL1, and 2DL2 ligand
interactions, at least in the case of aboriginal patients. On the
other hand, non-aboriginal patients may be affected by specific
3DL1 allotypes and a lack of 2DL1 allotype-ligands interactions.
In future studies, it would be interesting to determine the
distribution of specific 2DL1 and 2DL2/L3 allotypes, in
conjunction with their ligands, for a larger sample of H1N1/09
ICU patients. This would allow for further clarification and
characterization of the function, or lack thereof, of NK cells in
patients with severe responses.
Lastly, marked differences were found in the frequencies of two
synonymous allotypes, 3DL1*00401 and 3DL1*00402, between non-
aboriginal ICU patients and Caucasoids. Although highly speculative,
the mutations could produce two different proteins, possibly via
changes in mRNA stability or alternative splice sites [43,44]. Their
phenotypic effects, if any, will need to be further investigated.
In summary, among ICU patients with severe responses to
H1N1/09, 3DL1*00101, 3DL1*01502, and 3DL1*029, were
enriched in aboriginal ICU patients, while 3DL1*00401 and
3DL1*01502 were enriched in non-aboriginals ICU patients.
Likewise, the ligand-negative pairs KIR3DL1/S1
+ Bw6
+ Bw4
2
and KIR2DL1 C2
2 C1
+, and ligand-positive pair KIR2DL3 C1
+,
were also observed to be proportionally higher in ICU patients,
relative to healthy St. Theresa controls. As such, the study shows
that the enrichment of specific allotypes and a disproportional
distribution of cognate HLA class I ligands are likely factors that
mediated NK cell dysfunction and lead to the development of
severe responses to H1N1/09 in ICU patients.
Table 4. Comparison of average probabilities of death
among H1N1 ICU patients based on APACHE II severity of
disease classification system.
Aboriginal Non-Aboriginal
Allele/Ligand n
Death
Rate (%) n
Death
Rate (%)
2DL2/L3 C1
het 8 (40%) 36 9 (29%) 40
2DL2/L3 C1
hom 6 (30%) 43 22 (71%) 40
2DL2/L3 C2
hom 6 (30%) 38 - -
2DL2/L3 C1
+ 14 (70%) 39 9 (29%) 40
2DL2
+ C1
+ 3 (15%) 21 12 (39%) 38
2DL2
+ 2DL3
2 C1
+ 10 (50%) 46 19 (61%) 42
3DL1/S1 Bw4
het 10 (50%) 29 15 (48%) 41
3DL1/S1 Bw4
hom 4 (20%) 41 2 (7%) 48
3DL1/S1 Bw6
hom 6 (30%) 52 11 (36%) 39
3DL1/S1 Bw4
+ 14 (70%) 34 17 (55%) 43
Bw4
+ and C1
2 5 (25%) 35 - -
Bw4
2 and C1
+ 5 (25%) 52 10 (32%) 38
Bw4
+ and C2
+ C1
+/2 9 (45%) 28 6 (19%) 36
Bw4
2 and C2
+ C1
+/2 4 (20%) 51 1 (3%) 55
Bw4
+ and C1
+ C2
+ 5 (25%) 27 6 (19%) 36
3DL1*00101 Bw4
+ 5 (25%) 40 5 (16%) 37
3DL1*01502 Bw4
+ 4 (20%) 33 5 (16%) 48
3DL1*029 Bw4
+ 3 (15%) 52 - -
3DL1*00401 Bw4
+ - - 5 (16%) 58
3DS1*01301 Bw4-80I
+ 9 (45%) 32 8 (26%) 48
het, heterozygous; hom, homozygous.
doi:10.1371/journal.pone.0029200.t004
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Study Population
The study used data from two separate cohorts with a total of
156 subjects (125 Aboriginal, 27 Caucasoid, 2 South Asian, and 2
unknown/mix ethnics). The first cohort consisted of 51 H1N1/09
intensive-care unit (ICU) patients with severe cases of infection.
The second included 105 aboriginal H1N1-negative subjects from
St. Theresa Point. Screening of the St. Theresa Point population
was undertaken by analyzing DNA samples obtained in 2007–09,
in the context of a study evaluating the prevalence of rheumatoid
arthritis (RA) risk factors in the community. Individuals aged 18–
55 were randomly selected from the community at large based on
their willingness to participate in the RA study. All ICU patients
were H1N1-confirmed by RT-PCR testing.
Ethics Statement. Permission to use the St. Theresa Point
samples for the H1N1/09 study was specifically obtained from the
Research Ethics Board of the University of Manitoba and from the
leadership of the community through the Band Council. The study
of ICU patients was approved using a full consent process through
the Research Ethics Board of the University of Manitoba. The
data were analyzed anonymously.
KIR3DL1/S1 and HLA Genotyping
Genomic DNA was isolated from whole blood samples that
were stored in PAXgene Blood RNA tubes (PreAnalytix) using a
QIAmp DNA Mini Kit and the EZ1 BioRobot (QIAgen Inc,
Mississauga, Ontario, Canada).
PCR amplification. KIR3DL1/S1 exons 1–5, 7, and 9,
KIR2DL2/3 exon 4 [45], and HLA-B exons 2 and 3 [46] were
amplified using genomic DNA with gene-specific primers (Table 5).
PCR amplifications were confirmed by 1% agarose gel
electrophoresis with ethidium bromide. PCR products were
purified using Agencourt AMPure XP Kits (Beckman Coulter)
and resuspended in Tris-EDTA buffer (pH 8.0).
Sequencing. PCR products were sequenced using BigDye
TM
Terminator Cycle Sequencing Kits (Applied Biosystems) V1.1.
Purified PCR products were analyzed using an ABI PRISM
31306l Genetic Analyzer (Applied Biosystems) and genotyped
using Codon Express
TM, a taxonomy-based sequencing analysis
software, with the KIR and HLA databases from IMGT/HLA
and IPD/KIR, respectively [47–49].
Statistical Analysis
Frequency analysis was performed using SPSS 13.0 for
Windows. The statistical significance of difference between allele
frequencies were calculated using Fisher’s Exact Test for small
numbers via Microsoft Research and VassarStats [50,51].
Correct P values (Pc) were obtained using the Sidak method by
calculating 1-(1- P)
n, where n is the number of alleles analyzed in
each group. A P value of less than 0.05 was considered
significant.
Table 5. Amplification and sequencing primers for KIR3DL1/S1 typing.
Name Specificity Primer Sequence (59 39) Location Annealing Temperature
L1S1-1FPCR 59 Exon 1 CGAGGTGTCAATTCTAGTGAGAG Intron 1 61 to 51uC
c
L1S1-1RPCR 39 Exon 1 CACTTCAGGCCCATAACTCCAC Intron 2 61 to 51uC
c
L1S1-1FSEQ Exon 1 CGAGGTGTCAATTCTAGTGAGAG Intron 1 53.0uC
L1S1-1RSEQ Exon 1 CTAGGCCCATATCTTTACCTCC Intron 2 55.0uC
L1S1-2-3FPCR 59 Exon 2 GAGATCCTTGTTCCTGGGG Intron 2 56.2uC
L1S1-2-3RPCR 39 Exon 3 CGTCTCCCTCCCACTACAC Intron 3 56.2uC
L1S1-2FSEQ Exon 2 CAGCGAGGGTGAGTTTAC Intron 2 56.9uC
L1S1-2RSEQ Exon 2 GAGGGTCCCCTCTTCCTAGTG Intron 3 55.0uC
L1S1-3FSEQ Exon 3 GTGGAAATGGGGAGAATCTTCTGG Intron 3 55.0uC
L1S1-3RSEQ Exon 3 CAGAAGCTCTGGGATTCAG Intron 4 58.0uC
L1S1-4FPCR 59 Exon 4 CATGCAGCCTGTCCTCTTC Intron 4 57.6uC
L1S1-4RPCR 39 Exon 4 ACACGGCATCTGTAGGTGG Intron 5 57.6uC
L1S1-4FSEQ Exon 4 GGGAGGAGAGAGACAGACACG Intron 4 53.0uC
L1S1-4RSEQ Exon 4 CAGACCTCACCAAGTCAC Intron 5 52.0uC
L1S1-5FPCR 59 Exon 5 GACAGAGAGGCAGACAGAGAGG Intron 5 64 to 54uC
c
L1S1-5RPCR 39 Exon 5 CTGACTCCGCCCTCACACCTG Intron 6 64 to 54uC
c
L1S1-5FSEQ Exon 5 GAGAGAGAGAGAGAGAGCATTAG Intron 5 55.0uC
L1S1-5RSEQ Exon 5 CTCTGCATCTGTCCATGCTTTTC Intron 6 55.0uC
L1S1-7-9FPCR
a 59 Exon 7 GCTATAACTGAGAAAGCAGGAGG Intron 7 64 to 54uC
c
L1S1-7-9RPCR
a 39 Exon 9 CATTTGTAAGCAAGWGAGAGGCAC Intron 9 64 to 54uC
c
L1S1-7FSEQ
a Exon 7 GGGTGCTTGTCCKAAAGAGAYGC Intron 7 58.9uC
L1-9FSEQ
a,b Exon 9 CACTCAGCATTTCCCTCCCTCAC Intron 9 54.4uC
L1-9RSEQ
a,b Exon 9 GGCTGTTGTCTCCCTAGAAGACG Intron 10 58.0uC
aDoes not amplify 3DL1*059, 3DL1*060, 3DL1*061.
b3DL1 only.
cTouchdown PCR temperature range.
doi:10.1371/journal.pone.0029200.t005
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